Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Mar 15, 2026; 18(3): 115812
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.115812
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.115812
Table 4 Summary of case reports of liver tuberculosis
| No. | Ref. | Age | Immune status | Lesion location | Diagnostic method | IGRA result | Treatment duration | Outcome |
| 1 | Chen et al[21], 2003 | 56 | Hepatitis C-related liver cirrhosis and end-stage renal disease | Liver segments IV, V | Ultrasound-guided biopsy | Not mentioned | Isoniazid, rifampicin, pyrazinamide, ethambutol for 6 months | Good recovery, asymptomatic at |
| 2 | Culafic et al[22], 2005 | 57 | Immunocompetent | Liver segments III, IV and peritoneum | Laparoscopic biopsy | Not mentioned | Isoniazid, rifampicin and pyrazinamide for 12 months | Good recovery |
| 3 | Köksal et al[23], 2006 | 48 | Diabetes mellitus | Posterior segment of right hepatic lobe | Ultrasound-guided percutaneous biopsy | Not mentioned | Isoniazid, rifampicin for 9 months; morphine floxacin, ethambutol for 3 months | Cure, abscess reduced in size |
| 4 | Kharrasse et al[5], 2014 | 44 | Benign gastroesophageal reflux disease | Hepatic SVIII segment | Liver biopsy | Not mentioned | Isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months, then isoniazid, rifampicin, and ethambutol for 4 months | Good recovery |
| 5 | Zhang et al[24], 2014 | 30 | Hepatitis B history, pulmonary tuberculosis | Liver (multiple nodules) | CT-guided fine needle aspiration biopsy | Not mentioned | Rifampicin, isoniazid, pyrazinamide, ethambutol, plus prednisone and dioxacin for 1 year | Recovery, weight gain, normal CT at 6 months |
| 6 | Liao et al[25], 2015 | 40 | Immunocompetent | Lung and liver | CT-guided percutaneous biopsy of the lung and liver | Not mentioned | INH, RFP, PZA, EMB (HRZE) | Symptoms relieved |
| 7 | Dawani et al[26], 2018 | 32 | Immunocompetent | Liver and spleen | Ultrasound-guided fine needle aspiration biopsy | Quantiferon-TB test negative | Anti-tuberculous therapy for 6 months | Recovery, weight gain, ultrasound normal at 15-month follow-up |
| 8 | Ai et al[27], 2018 | 45 | Immunocompetent | Liver (multiple masses) | Next-generation sequencing of liver tissue and ultrasound-guided biopsy | T-SPOT, TB positive | Rifampicin, isoniazid, ethambutol, pyrazinamide, levofloxacin | Symptom resolution, asymptomatic at |
| 9 | Liang et al[28], 2018 | 58 | Immunocompetent | Pancreas and liver | CT-guided fine needle aspiration biopsy of hepatic lesion | Not mentioned | Rifampicin, isoniazid, pyrazinamide, ethambutol for 2 months, then rifampicin and isoniazid for 4 months | Symptom resolution, asymptomatic at |
| 10 | Haque et al[29], 2019 | 58 | Immunocompetent | Liver and gallbladder region | Peroperative frozen section biopsy | Not mentioned | Anti-tuberculous treatment for 1 year | Improvement, symptoms disappeared, weight gain |
| 11 | Pang et al[30], 2019 | 15 | Immunocompetent | Hilar region of the liver | Postoperative pathological examination | The results of TBAB and T-SPOT were negative | Systemic anti tuberculosis treatment, a total of 6 months | Symptoms disappeared completely |
| 12 | Alsaif et al[31], 2021 | 47 | Immunocompetent | Liver (HCC and tuberculosis co-existing) | CT-guided biopsy | Not mentioned | Rifampicin, isoniazid, ethambutol, levofloxacin; duration not specified | Clinical improvement, fever resolved, tumor not resected |
| 13 | Hao et al[32], 2023 | 38 | Hepatitis B history, hepatobiliary adenocarcinoma | Liver | Postoperative pathology | Not mentioned | Standard antituberculous treatment for 1 year | Recovery well |
| 14 | Hao et al[32], 2023 | 51 | Immunocompetent | Liver | Laparoscopic biopsy | Not mentioned | Rifampicin, isoniazid, pyrazinamide, ethambutol for 2 months, then rifampicin and isoniazid for 4 months | Abdominal pain resolved, good outcome |
- Citation: Qi DY, Zhao YC, Chen LP. Isolated hepatic tuberculoma: A case report and review of the literature. World J Gastrointest Oncol 2026; 18(3): 115812
- URL: https://www.wjgnet.com/1948-5204/full/v18/i3/115812.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i3.115812